Cargando…

The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials

OBJECTIVE: To characterize the financial toxicity experienced by advanced cancer patients enrolled in phase I oncology trials. PATIENTS AND METHODS: We conducted structured interviews with cancer patients participating in phase I clinical trials. Using a thematic analysis approach, we identified rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Colt, Meyer, Leigh, Kawam, Omar, Leventakos, Konstantinos, DeMartino, Erin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685144/
https://www.ncbi.nlm.nih.gov/pubmed/38035050
http://dx.doi.org/10.1016/j.mayocpiqo.2023.09.003
_version_ 1785151563847696384
author Williams, Colt
Meyer, Leigh
Kawam, Omar
Leventakos, Konstantinos
DeMartino, Erin S.
author_facet Williams, Colt
Meyer, Leigh
Kawam, Omar
Leventakos, Konstantinos
DeMartino, Erin S.
author_sort Williams, Colt
collection PubMed
description OBJECTIVE: To characterize the financial toxicity experienced by advanced cancer patients enrolled in phase I oncology trials. PATIENTS AND METHODS: We conducted structured interviews with cancer patients participating in phase I clinical trials. Using a thematic analysis approach, we identified recurring themes in patients’ experiences of financial toxicity resulting from trial participation. RESULTS: Seven major themes emerged from the interviews: (1) the burden of travel, (2) a willingness to pursue treatment despite financial risk, (3) fear of destitution, (4) financial toxicity equaling physical toxicity, (5) changes in food spending, (6) reluctance to confide in the study investigator about financial toxicity, and (7) difficulty navigating financial aid. These themes highlight the multifaceted financial challenges faced by patients in early phase clinical trials and the need for targeted support services. CONCLUSION: Our findings underscore the relevance of financial toxicity in the context of phase I clinical trials and provide insights into the diverse challenges faced by advanced cancer patients. These challenges likely augment the disparities seen in trial enrollment for historically marginalized populations. Addressing financial toxicity in this population is crucial for improving patient outcomes and quality of life. Future research should focus on developing effective interventions and support services tailored to the needs of patients in early phase clinical trials.
format Online
Article
Text
id pubmed-10685144
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106851442023-11-30 The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials Williams, Colt Meyer, Leigh Kawam, Omar Leventakos, Konstantinos DeMartino, Erin S. Mayo Clin Proc Innov Qual Outcomes Original Article OBJECTIVE: To characterize the financial toxicity experienced by advanced cancer patients enrolled in phase I oncology trials. PATIENTS AND METHODS: We conducted structured interviews with cancer patients participating in phase I clinical trials. Using a thematic analysis approach, we identified recurring themes in patients’ experiences of financial toxicity resulting from trial participation. RESULTS: Seven major themes emerged from the interviews: (1) the burden of travel, (2) a willingness to pursue treatment despite financial risk, (3) fear of destitution, (4) financial toxicity equaling physical toxicity, (5) changes in food spending, (6) reluctance to confide in the study investigator about financial toxicity, and (7) difficulty navigating financial aid. These themes highlight the multifaceted financial challenges faced by patients in early phase clinical trials and the need for targeted support services. CONCLUSION: Our findings underscore the relevance of financial toxicity in the context of phase I clinical trials and provide insights into the diverse challenges faced by advanced cancer patients. These challenges likely augment the disparities seen in trial enrollment for historically marginalized populations. Addressing financial toxicity in this population is crucial for improving patient outcomes and quality of life. Future research should focus on developing effective interventions and support services tailored to the needs of patients in early phase clinical trials. Elsevier 2023-11-15 /pmc/articles/PMC10685144/ /pubmed/38035050 http://dx.doi.org/10.1016/j.mayocpiqo.2023.09.003 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Williams, Colt
Meyer, Leigh
Kawam, Omar
Leventakos, Konstantinos
DeMartino, Erin S.
The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials
title The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials
title_full The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials
title_fullStr The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials
title_full_unstemmed The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials
title_short The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials
title_sort faces of financial toxicity: a qualitative interview study of financial toxicity in advanced cancer patients in phase i oncology trials
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685144/
https://www.ncbi.nlm.nih.gov/pubmed/38035050
http://dx.doi.org/10.1016/j.mayocpiqo.2023.09.003
work_keys_str_mv AT williamscolt thefacesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials
AT meyerleigh thefacesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials
AT kawamomar thefacesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials
AT leventakoskonstantinos thefacesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials
AT demartinoerins thefacesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials
AT williamscolt facesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials
AT meyerleigh facesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials
AT kawamomar facesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials
AT leventakoskonstantinos facesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials
AT demartinoerins facesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials